

**IN THE SPECIFICATION:**

Amend the specification as follows:

Delete the paragraph spanning lines 11-13 of Page 10 and insert the following new paragraph therefor:

(6) The derivative of an antibody according to (2), wherein the antibody produced by a hybridoma is KM641 (KM641 has been deposited on September 27, 1990, under the conditions of the Budapest Treaty, as FERM BP-3116 in Fermentation Research Institute, Agency of Industrial Science and Technology Higashi 1-1-3, Tsukuba, Ibaraki, Japan (now the International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology Central 6, Higashi 1-1-1, Tsukuba, Ibaraki, Japan)).

Delete the paragraph spanning lines 24-26 of Page 20 and insert the following new paragraph therefor:

Examples of the anti-GD3 chimeric antibody include KM871 described in Japanese Published Unexamined Patent Application No. 304989/93. (KM871 has been deposited on August 13, 1991, under the conditions of the Budapest Treaty, as FERM BP-3512 in Fermentation Research Institute, Agency of Industrial Science and Technology Higashi 1-1-3, Tsukuba, Ibaraki, Japan (now the International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology Central 6, Higashi 1-1-1, Tsukuba, Ibaraki, Japan)).

Delete the paragraph spanning lines 10-16 of Page 97 and insert the following new paragraph therefor:

The transformed cell clone KM8871 capable of producing KM8871 which showed the most high activity among the anti-GD3 CDR-grafted antibodies has been deposited on July 22, 1999, under the conditions of the Budapest Treaty, as FERM BP-6790 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology (Higashi 1-1-3, Tsukuba, Ibaraki, Japan (now the International Patent Organism Depository, National Institute of Advanced Industrial Science and Technology Central 6, Higashi 1-1-1, Tsukuba, Ibaraki, Japan)).